Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years.
Identifieur interne : 004A11 ( Ncbi/Checkpoint ); précédent : 004A10; suivant : 004A12Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years.
Auteurs : A J Hughes [Royaume-Uni] ; S. Bishop ; B. Kleedorfer ; N. Turjanski ; W. Fernandez ; A J Lees ; G M SternSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 1993.
English descriptors
- KwdEn :
- Adult, Aged, Apomorphine (administration & dosage), Apomorphine (adverse effects), Female, Follow-Up Studies, Humans, Infusion Pumps, Injections, Subcutaneous, Levodopa (administration & dosage), Levodopa (adverse effects), Long-Term Care, Male, Middle Aged, Neurologic Examination (drug effects), Parkinson Disease (drug therapy).
- MESH :
- chemical , administration & dosage : Apomorphine, Levodopa.
- chemical , adverse effects : Apomorphine, Levodopa.
- drug effects : Neurologic Examination.
- drug therapy : Parkinson Disease.
- Adult, Aged, Female, Follow-Up Studies, Humans, Infusion Pumps, Injections, Subcutaneous, Long-Term Care, Male, Middle Aged.
Abstract
Subcutaneous apomorphine, administered by continuous waking-day infusion with boluses, or by repeated intermittent injection, was given to 71 parkinsonian patients with severe refractory levodopa related on-off fluctuations for 1-5 years. A mean reduction in daily off period time of approximately 50% was maintained, and the incidence of neuropsychiatric toxicity remained low on long-term follow-up. No clinically significant tolerance or loss of therapeutic effect was seen, although increasingly severe on-phase dyskinesias and postural instability marred the long-term therapeutic response in many patients. Despite these drawbacks, apomorphine, when combined with the peripheral dopamine receptor agonist domperidone, represents a significant therapeutic advance in the management of late-stage Parkinson's disease and should certainly be considered before experimental implantation procedures.
DOI: 10.1002/mds.870080208
PubMed: 8474483
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 004C55
- to stream PubMed, to step Curation: 004C55
- to stream PubMed, to step Checkpoint: 004B98
- to stream Ncbi, to step Merge: 004A11
- to stream Ncbi, to step Curation: 004A11
Links to Exploration step
pubmed:8474483Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years.</title><author><name sortKey="Hughes, A J" sort="Hughes, A J" uniqKey="Hughes A" first="A J" last="Hughes">A J Hughes</name><affiliation wicri:level="2"><nlm:affiliation>Department of Neurology, Middlesex Hospital, London, England.</nlm:affiliation><country>Royaume-Uni</country><placeName><region type="country">Angleterre</region></placeName><wicri:cityArea>Department of Neurology, Middlesex Hospital, London</wicri:cityArea></affiliation></author><author><name sortKey="Bishop, S" sort="Bishop, S" uniqKey="Bishop S" first="S" last="Bishop">S. Bishop</name></author><author><name sortKey="Kleedorfer, B" sort="Kleedorfer, B" uniqKey="Kleedorfer B" first="B" last="Kleedorfer">B. Kleedorfer</name></author><author><name sortKey="Turjanski, N" sort="Turjanski, N" uniqKey="Turjanski N" first="N" last="Turjanski">N. Turjanski</name></author><author><name sortKey="Fernandez, W" sort="Fernandez, W" uniqKey="Fernandez W" first="W" last="Fernandez">W. Fernandez</name></author><author><name sortKey="Lees, A J" sort="Lees, A J" uniqKey="Lees A" first="A J" last="Lees">A J Lees</name></author><author><name sortKey="Stern, G M" sort="Stern, G M" uniqKey="Stern G" first="G M" last="Stern">G M Stern</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1993">1993</date><idno type="RBID">pubmed:8474483</idno><idno type="pmid">8474483</idno><idno type="doi">10.1002/mds.870080208</idno><idno type="wicri:Area/PubMed/Corpus">004C55</idno><idno type="wicri:Area/PubMed/Curation">004C55</idno><idno type="wicri:Area/PubMed/Checkpoint">004B98</idno><idno type="wicri:Area/Ncbi/Merge">004A11</idno><idno type="wicri:Area/Ncbi/Curation">004A11</idno><idno type="wicri:Area/Ncbi/Checkpoint">004A11</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years.</title><author><name sortKey="Hughes, A J" sort="Hughes, A J" uniqKey="Hughes A" first="A J" last="Hughes">A J Hughes</name><affiliation wicri:level="2"><nlm:affiliation>Department of Neurology, Middlesex Hospital, London, England.</nlm:affiliation><country>Royaume-Uni</country><placeName><region type="country">Angleterre</region></placeName><wicri:cityArea>Department of Neurology, Middlesex Hospital, London</wicri:cityArea></affiliation></author><author><name sortKey="Bishop, S" sort="Bishop, S" uniqKey="Bishop S" first="S" last="Bishop">S. Bishop</name></author><author><name sortKey="Kleedorfer, B" sort="Kleedorfer, B" uniqKey="Kleedorfer B" first="B" last="Kleedorfer">B. Kleedorfer</name></author><author><name sortKey="Turjanski, N" sort="Turjanski, N" uniqKey="Turjanski N" first="N" last="Turjanski">N. Turjanski</name></author><author><name sortKey="Fernandez, W" sort="Fernandez, W" uniqKey="Fernandez W" first="W" last="Fernandez">W. Fernandez</name></author><author><name sortKey="Lees, A J" sort="Lees, A J" uniqKey="Lees A" first="A J" last="Lees">A J Lees</name></author><author><name sortKey="Stern, G M" sort="Stern, G M" uniqKey="Stern G" first="G M" last="Stern">G M Stern</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="1993" type="published">1993</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Apomorphine (administration & dosage)</term><term>Apomorphine (adverse effects)</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Infusion Pumps</term><term>Injections, Subcutaneous</term><term>Levodopa (administration & dosage)</term><term>Levodopa (adverse effects)</term><term>Long-Term Care</term><term>Male</term><term>Middle Aged</term><term>Neurologic Examination (drug effects)</term><term>Parkinson Disease (drug therapy)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Apomorphine</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Apomorphine</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Neurologic Examination</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Infusion Pumps</term><term>Injections, Subcutaneous</term><term>Long-Term Care</term><term>Male</term><term>Middle Aged</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Subcutaneous apomorphine, administered by continuous waking-day infusion with boluses, or by repeated intermittent injection, was given to 71 parkinsonian patients with severe refractory levodopa related on-off fluctuations for 1-5 years. A mean reduction in daily off period time of approximately 50% was maintained, and the incidence of neuropsychiatric toxicity remained low on long-term follow-up. No clinically significant tolerance or loss of therapeutic effect was seen, although increasingly severe on-phase dyskinesias and postural instability marred the long-term therapeutic response in many patients. Despite these drawbacks, apomorphine, when combined with the peripheral dopamine receptor agonist domperidone, represents a significant therapeutic advance in the management of late-stage Parkinson's disease and should certainly be considered before experimental implantation procedures.</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li></country><region><li>Angleterre</li></region></list><tree><noCountry><name sortKey="Bishop, S" sort="Bishop, S" uniqKey="Bishop S" first="S" last="Bishop">S. Bishop</name><name sortKey="Fernandez, W" sort="Fernandez, W" uniqKey="Fernandez W" first="W" last="Fernandez">W. Fernandez</name><name sortKey="Kleedorfer, B" sort="Kleedorfer, B" uniqKey="Kleedorfer B" first="B" last="Kleedorfer">B. Kleedorfer</name><name sortKey="Lees, A J" sort="Lees, A J" uniqKey="Lees A" first="A J" last="Lees">A J Lees</name><name sortKey="Stern, G M" sort="Stern, G M" uniqKey="Stern G" first="G M" last="Stern">G M Stern</name><name sortKey="Turjanski, N" sort="Turjanski, N" uniqKey="Turjanski N" first="N" last="Turjanski">N. Turjanski</name></noCountry><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Hughes, A J" sort="Hughes, A J" uniqKey="Hughes A" first="A J" last="Hughes">A J Hughes</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004A11 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd -nk 004A11 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Checkpoint
|type= RBID
|clé= pubmed:8474483
|texte= Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/RBID.i -Sk "pubmed:8474483" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |